Beclate 200 RC Capsule
Beclomethasone Dipropionate
200mcg
Cipla Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 128.00 NPR |
Indications
Beclate 200 RC Capsule is used for:
Asthma, Chronic obstructive pulmonary disease (COPD),
Adult Dose
Management of chronic asthma
Adults: 100-400 mcg twice daily.
Prophylaxis of asthma
Adults: 50-200 mcg twice daily. Increased if necessary to maximum 400 mcg twice daily.
When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.
Child Dose
Management of chronic asthma
Children over 12 years: 100-400 mcg twice daily.
Children (5-12 years): 100-200 mcg twice daily. Maximum 200-400 mcg twice daily.
Prophylaxis of asthma
Children over 12 years: 50-200 mcg twice daily. Increased if necessary to maximum 400 mcg twice daily.
Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.
When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.
Renal Dose
Administration
Prime inhaler (2 actuations into air) before first use and after prolonged idleness (>10 days)
Contra Indications
Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Child under 6 years not recommended.
Precautions
Patients should be instructed to use inhaler properly to ensure that the drug reaches the target areas within the lungs. They should also be made aware of the prophylactic nature of therapy with Beclometasone Dipropionate HFA inhaler and that they should use it regularly, even when they are asymptomatic.
Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients.
Beclometasone dipropionate is not suitable for the treatment of an acute asthma attack.
Lactation: Potential for excretion into milk; use only if benefits greatly outweigh risks
Pregnancy-Lactation
Interactions
Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations).
Inducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations).
Antidiabetic agents
May increase blood glucose concentrations in patients with diabetes mellitus.
NSAIDs
Possible increased risk of GI ulcerationa
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication
Vaccines and Toxoids
May cause a diminished response to toxoids and live or inactivated vaccines.
May potentiate replication of some organisms contained in live, attenuated vaccines.
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages).
Adverse Effects
Side effects of Beclomethasone Dipropionate :
>10%
Pharyngitis (5-27%),Headache (8-25%),URI (5-11%)
1-10%
Rhinitis (3-7%),Pain (1-5%),Increased asthma symptoms (2-4%),Dysphonia (1-4%),Sinusitis (3%),Oral symptoms (2-3%),Nausea (1-2%)
Mechanism of Action
Beclometasone controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
Note
Beclate 200 RC 200mcg Capsule manufactured by Cipla Ltd.. Its generic name is Beclomethasone Dipropionate. Beclate 200 RC is availble in Nepal.
Farmaco Nepal drug index information on Beclate 200 RC Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.